Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.50 |
| ▸ | GRM5 | P41594 | 10/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381767 | 0.89 | GPR119 (0.52) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL13993114 | 0.88 | PDK4 (0.53) | NAMPTPDK4GRM1GRM5TNK2 | |
| SCHEMBL8193684 | 0.86 | NAMPT (0.59) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL31466040 | 0.86 | GRM1 (0.55) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL2297459 | 0.85 | NAMPT (0.58) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL2594283 | 0.85 | GRM1 (0.65) | NAMPTPDK4GRM1GRM5 | |
| SCHEMBL8912847 | 0.84 | NAMPT (0.63) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL904049 | 0.83 | NAMPT (0.61) | NAMPTGPR119PDK4GRM1GRM5 | |
| SCHEMBL4949303 | 0.83 | TRPV1 (0.45) | — | |
| SCHEMBL18619842 | 0.82 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | GUANGDONG GOOD MEDICINE AND HEALTH TECHNOLOGY CO., LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | NAMPT 1000/4885GPR119 4482/4885PDK4 2780/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | NAMPT 1000/4885GPR119 4482/4885PDK4 2780/4885 |
| US-20170313697-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF | ABCG2, ABCC1, PNPO | NAMPT 286/4885GPR119 3243/4885PDK4 630/4885 |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | NAMPT 3926/4885GPR119 86/4885PDK4 1921/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | NAMPT 1000/4885GPR119 4482/4885PDK4 2780/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | NAMPT 3926/4885GPR119 86/4885PDK4 1921/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | NAMPT 609/4885GPR119 4215/4885PDK4 3167/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | NAMPT 2518/4885GPR119 2739/4885PDK4 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.